October 29, 2018
Taiho Pharmaceutical said on October 26 that the US FDA has accepted an application for its anticancer treatment Lonsurf (trifluridine + tipiracil) for an additional indication of gastric cancer. The drug has also been assigned priority review status. The application...read more